» Articles » PMID: 38067235

Real-World Systemic Treatment Patterns After Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067235
Authors
Affiliations
Soon will be listed here.
Abstract

Real-world (RW) evidence is needed to evaluate atezolizumab plus bevacizumab (atezo + bev) utilization for hepatocellular carcinoma (HCC) in clinical practice. This retrospective cohort study used administrative claims databases to evaluate treatment patterns in individuals with HCC ≥18 years of age who were initiated on atezo + bev between June 2020 and June 2022. The endpoints of this study were the proportion of individuals who discontinued atezo + bev and received subsequent systemic therapies, time to discontinuation (TTD), and time to next treatment. Overall, 825 individuals were eligible (median age 67 years; 80% male). Over a median follow-up of 15.3 months, most (72%) discontinued atezo + bev, with a median TTD of 3.5 months. A minority (19%) received subsequent therapies, with the most common second-line agents being lenvatinib (6%), cabozantinib (4%), and nivolumab (4%). The median time from index to next treatment post-atezo + bev was 5.4 months. Further research is needed to identify the patients who are most likely to benefit from atezo + bev as well as later-line HCC therapies to optimize overall survival.

Citing Articles

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K Medicine (Baltimore). 2024; 103(34):e39289.

PMID: 39288227 PMC: 11346847. DOI: 10.1097/MD.0000000000039289.

References
1.
Mokdad A, Zhu H, Marrero J, Mansour J, Singal A, Yopp A . Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. Am J Gastroenterol. 2016; 111(7):967-75. DOI: 10.1038/ajg.2016.181. View

2.
Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

3.
Kudo M . Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel). 2021; 13(21). PMC: 8582435. DOI: 10.3390/cancers13215475. View

4.
Delis S, Dervenis C . Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008; 14(22):3452-60. PMC: 2716604. DOI: 10.3748/wjg.14.3452. View

5.
Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M . Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?. Target Oncol. 2023; 18(2):221-233. DOI: 10.1007/s11523-023-00953-x. View